Mendelian randomization study of lipid metabolism characteristics and migraine risk
European Journal of Pain · 2024
DOI: 10.1002/ejp.2235 ↗At a glance
Journal article in European Journal of Pain, 2024. Written by Peiwei Hong and 2 co-authors. Institution: Department of Neurology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, People's Republic of China. Major MEDLINE topics: Mendelian Randomization Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Lipid Metabolism. Cited 8 times so far (Crossref); 40 references.
Abstract (original language)
Background
The association between serum lipids and migraine is controversial. However, randomized controlled trials have suggested that statins may be efficacious for the prevention of migraine. In this study, we aim to investigate the relationship between lipids metabolism and migraine risk.
Methods
Single‐nucleotide polymorphisms (SNPs), relating to the serum lipid traits and the effect of lipid‐lowering drugs that target APOB , CETP , HMGCR , NPC1L1 , and PCSK9 , were extracted from genome‐wide association studies (GWAS) summary data. The GWAS summary data were obtained from the Global Lipids Genetic Consortium (GLGC), the UK Biobank, and the FinnGen study, respectively. Mendelian randomization (MR) analysis was performed to evaluate the association between serum lipid traits and lipid‐lowering drugs with migraine risk.
Results
Regarding serum lipids, it was found that SNPs related to high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), non‐high‐density lipoprotein cholesterol (non‐HDL‐C), total cholesterol (TC), or triglycerides (TG) levels were not associated with migraine, migraine with aura (MA) or migraine without aura (MO). In addition, genotypes of HMGCR related to higher LDL‐C levels were associated with increased risk of migraine (OR = 1.46, p = 0.035) and MA (OR = 2.03, p = 0.008); However, genotypes of PCSK9 related to higher LDL‐C levels were associated with decreased risk of migraine (OR = 0.75, p = 0.001) and MA (OR = 0.69, p = 0.004); And genotypes of APOB related to higher LDL‐C levels were associated with decreased risk of MO (OR = 0.62, p = 0.000).
Conclusions
There is a relationship between lipid metabolism characteristics and migraine risk. Significance Based on the genome‐wide association summary data, single‐nucleotide polymorphisms (SNPs) related to high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), non‐high‐density lipoprotein cholesterol (non‐HDL‐C), total cholesterol (TC), or triglycerides (TG) level were not associated with risk of migraine, migraine with aura (MA) or migraine without aura (MO). However, genotypes of HMGCR related to higher LDL‐C levels have shown an increased risk on migraine and MA. And genotypes of APOB or PCSK9 related to higher LDL‐C levels have shown a decreased risk on MO, or migraine and MA, respectively. These results suggested that there may be a relationship between lipid metabolism characteristics and the risk for migraine development.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Neurology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, People's Republic of China.
- West China-PUMC C.C. Chen Institute of Health, Sichuan University, Chengdu, People's Republic of China.
ORCID profiles: Peiwei Hong
Cite
APA
Hong, P., Han, L., & Wan, Y. (2024). Mendelian randomization study of lipid metabolism characteristics and migraine risk. European Journal of Pain. https://doi.org/10.1002/ejp.2235
Vancouver
Hong P, Han L, Wan Y. Mendelian randomization study of lipid metabolism characteristics and migraine risk. European Journal of Pain. 2024. doi:10.1002/ejp.2235
BibTeX
@article{Hong2024,
author = {Hong, Peiwei and Han, Lin and Wan, Yang},
title = {Mendelian randomization study of lipid metabolism characteristics and migraine risk},
journal = {European Journal of Pain},
year = {2024},
doi = {10.1002/ejp.2235}
}
EUVIMED